Edition:
India

Morphosys: Licensee Janssen Receives U.S. FDA Approval For Tremfya(R) One-Press Patient-Controlled Injector For Adults With Moderate-To-Severe Plaque Psoriasis


Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - MORPHOSYS AG ::ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED U.S. FDA APPROVAL FOR TREMFYA(R) ONE-PRESS PATIENT-CONTROLLED INJECTOR FOR ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS. 

Company Quote

97.15
-1.35 -1.37%
8:07pm IST